Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Vebreltinib |
| Trade Name | |
| Synonyms | Bozitinib|PLB1001|PLB-1001|APL-101|APL 101|APL101 |
| Drug Descriptions |
Vebreltinib (PLB-1001) is an ATP-competitive, small molecule inhibitor of MET, which is able to permeate the blood brain barrier and may inhibit downstream signaling and block tumor growth (PMID: 30343896). |
| DrugClasses | MET Inhibitor 59 |
| CAS Registry Number | 1440964-89-5 |
| NCIT ID | C129717 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Osimertinib + Vebreltinib | Osimertinib Vebreltinib | 0 | 1 |
| PLB1004 + Vebreltinib | PLB1004 Vebreltinib | 0 | 0 |
| Vebreltinib | Vebreltinib | 0 | 1 |